BioCentury
ARTICLE | Company News

Ligand receives approvable letter

June 12, 2000 7:00 AM UTC

LGND received an approvable letter from the FDA for Targretin bexarotene gel to treat cutaneous lesions in patients with early stage cutaneous T cell lymphoma (CTCL) who have not tolerated other thera...